Thanks for that - it makes sense. You'd think if the FDA are involved here, they will only add more weight to the scientific data.
The FDA wouldn't allow for EAP and P3 trial on Rem-L for Covid-19 ARDS; and MIS-C EAP and then turn around and not providing supporting data
So all good here. Again, no concerns at all!
Cell Therapy News/Articles, page-4943
-
- There are more pages in this discussion • 13,495 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |